Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials

Abstract Objective Previous studies showed that the combination of bevacizumab and erlotinib (combination therapy) significantly prolonged progression-free survival (PFS) but no overall survival (OS) compared to erlotinib alone (monotherapy) for advanced EGFR-mutant non-small cell lung cancer (NSCLC...

Full description

Bibliographic Details
Main Authors: Ruijian Li, Weiyi Li, Fang Zhang, Shanshan Li
Format: Article
Language:English
Published: BMC 2023-08-01
Series:European Journal of Medical Research
Subjects:
Bevacizumab
Erlotinib
Non-small cell lung cancer
Subgroup
Meta-analysis
Online Access:https://doi.org/10.1186/s40001-023-01272-7

Internet

https://doi.org/10.1186/s40001-023-01272-7

Similar Items